Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
Titel:
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
Auteur:
Rigby, Mark R DiMeglio, Linda A Rendell, Marc S Felner, Eric I Dostou, Jean M Gitelman, Stephen E Patel, Chetanbabu M Griffin, Kurt J Tsalikian, Eva Gottlieb, Peter A Greenbaum, Carla J Sherry, Nicole A Moore, Wayne V Monzavi, Roshanak Willi, Steven M Raskin, Philip Moran, Antoinette Russell, William E Pinckney, Ashley Keyes-Elstein, Lynette Howell, Michael Aggarwal, Sudeepta Lim, Noha Phippard, Deborah Nepom, Gerald T McNamara, James Ehlers, Mario R